Premium
Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of A ustralia M edical and S cientific A dvisory G roup
Author(s) -
Quach H.,
Joshua D.,
Ho J.,
Szer J.,
Spencer A.,
Harrison S.,
Mollee P.,
Roberts A.,
Horvath N.,
Talaulikar D.,
To B.,
Zannettino A.,
Brown R.,
Catley L.,
Augustson B.,
Jaksic W.,
Gibson J.,
Prince H. M.
Publication year - 2015
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.12688
Subject(s) - medicine , multiple myeloma , position statement , stem cell , transplantation , autologous stem cell transplantation , oncology , intensive care medicine , family medicine , genetics , biology
Options for treatment of elderly patients with multiple myeloma have expanded substantially following the development of immunomodulatory drugs ( IMiD ), proteasome inhibitors and with enhancement in safety of high‐dose therapy and autologous stem cell transplant ( HDT + ASCT ). The recognition of biological heterogeneity among elderly patients has made delivery of therapy more challenging. An individualised approach to treatment selection is recommended in an era in which highly efficacious treatment options are available for transplant‐ineligible patients. Here, we summarise recommendations for patients who are considered unsuitable for HDT + ASCT , including pretreatment considerations, and induction, maintenance and supportive care therapies.